This brand name is authorized in Nigeria.
The drug IMAZOLE PLUS contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
140QMO216E - METRONIDAZOLE
|
|
Metronidazole is an anti-infectious drug belonging to the pharmacotherapeutic group of nitroimidazole derivatives, which have effect mainly on strict anaerobes. This effect is probably caused by interaction with DNS and different metabolites. |
|
2
|
UNII
G07GZ97H65 - CLOTRIMAZOLE
|
|
Clotrimazole acts against fungi by inhibiting ergosterol synthesis. Inhibition of ergosterol synthesis leads to structural and functional impairment of the fungal cytoplasmic membrane. Clotrimazole has a broad antimycotic spectrum of action in vitro and in vivo, which includes dermatophytes, yeasts, moulds, etc. |
|
3
|
|
This drug has been approved in Nigeria as follows:
| Identifier | Form | Presentation | Description | Approval |
|---|---|---|---|---|
| B4-8584 | Pessary | Imazole Plus SUPP 500 mg; 100 mg; 150 million spores 1 x 6's | Vaginal Pessary White to off white bullet shaped pessaries | 25/02/2021 |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| NG | Registered Drug Product Database | B4-8584 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.